CIC
AMRX icon

Cornercap Investment Counsel’s Amneal Pharmaceuticals AMRX Stock Holding History

Cornercap Investment Counsel’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,013
Closed -$465K – 568
2023
Q2 		$465K Buy
150,013
+497
+0.3% +$1.06K 0.08% 415
2023
Q1 		$208K Hold
149,516
– – 0.04% 501
2022
Q4 		$298K Hold
149,516
– – 0.05% 470
2022
Q3 		$302K Buy
+149,516
New +$419K 0.06% 449

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornercap Investment Counsel's AMRX Position: Q3 2023 in Review

Cornercap Investment Counsel sold out of Amneal Pharmaceuticals (AMRX) in Q3 2023, closing a stake of 150,013 shares — an estimated $465K sold.

Cornercap Investment Counsel first reported a position in AMRX in Q3 2022 and held it in 4 quarters. The position peaked at $465K in Q2 2023. 144 funds tracked by Wall St. Rank hold AMRX as of Q3 2023.

  • Cornercap Investment Counsel reported no remaining Amneal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 150,013 Amneal Pharmaceuticals shares in Q3 2023, an estimated $465K.
  • Cornercap Investment Counsel first reported a position in Amneal Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Cornercap Investment Counsel's Amneal Pharmaceuticals position peaked at $465K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2023.

Based on Cornercap Investment Counsel's 13F filing for Q3 2023, filed 13 Nov 2023.